About OJO | Search | Ahead of print | Current Issue | Archives | Author Instructions | Reviewer Guidelines | Online submissionLogin 
Oman Journal of Ophthalmology Oman Journal of Ophthalmology
  Editorial Board | Subscribe | Advertise | Contact
https://www.omanophthalmicsociety.org/ Users Online: 1152  Wide layoutNarrow layoutFull screen layout Home Print this page  Email this page Small font size Default font size Increase font size
Year : 2020  |  Volume : 13  |  Issue : 1  |  Page : 43-45

Intralesional bleomycin: A treatment modality for conjunctival lymphangioma

Department of Oculoplasty, Dr. Shroff's Charity Eye Hospital, New Delhi, India

Correspondence Address:
Dr. Smriti Bansal
Department of Oculoplasty, Dr. Shroff's Charity Eye Hospital, Daryaganj, New Delhi
Login to access the Email id

Source of Support: None, Conflict of Interest: None

DOI: 10.4103/ojo.OJO_44_2019

Rights and Permissions

Lymphangioma is a benign hamartomatous lesion of vascular system which frequently involves orbit and ocular adnexa. A 35-year-old male patient presented with a subconjunctival mass extending from limbus to fornices. There was a history of recurrent swellings following episodes of upper respiratory tract infection. Bleomycin is an antineoplastic agent which acts on endothelial cells of the vascular channels, helps in collapsing the cystic cavity, and prevents its recurrence. We report a case where only bleomycin injection has been used intralesionally at multiple spots and patients have shown good cosmetic outcome without any recurrence noted after 1 year of follow-up.

Print this article     Email this article
 Next article
 Previous article
 Table of Contents

 Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
 Citation Manager
 Access Statistics
 Reader Comments
 Email Alert *
 Add to My List *
 * Requires registration (Free)

 Article Access Statistics
    PDF Downloaded96    
    Comments [Add]    
    Cited by others 1    

Recommend this journal